1. The Ministry of Health of Russian Federation 22.04.15. Instructions for use of the drug for medical use of tysabri. (In Russ.).
2. Alifirova VM, Bakhtiyarova KZ, Belova AN, Bisaga GN, Boyko AN, Vlasov YV, Volkova LI, Gavrilenko AA, Guekht AB, Gusev EI, Davydovskaya MV, Evdoshenko EP, Zakharova MN, Kotov SV, Lapin SV, Malkova NA, Petrov AM, Popova NF, Sivertseva SA, Skoromets AG, Stolyarov ID, Streknev AG, Totolyan NA, Schmidt TE, Khabirov FA, Khachanova NV, Yakupov EZ. Recommendation for use of new drugs (tysabri, gylenia, movectro) for pathogenic multiple sclerosis treatment. M.: ROOI «Zdorovie cheloveka»; 2011. (In Russ.).
3. Boyko AN, Boyko OV, Gusev EI. The choice of the optimal drug for pathogenic treatment of multiple sclerosis: a current state of the problem. Zhurnal nevrologii I psikhiatrii imeni S.S. Korsakova. 2014;114:10(2):77-91. (In Russ.).
4. Boyko AN, Evdoshenko EP, Vorobyeva OV, You X, Pukaite V. Prospective, open, non-randomized clinical trial on the safety and efficacy of natalizumab (tysabri) in the Russian population of patients with relapsing-remitting multiple sclerosis. Zhurnal nevrologii I psikhiatrii imeni S.S. Korsakova. 2015;115:8(2):25-35. (In Russ.).
5. Davydovskaya MV. Risk management plan for natalizumab therapy. Zhurnal nevrologii I psikhiatrii imeni S.S. Korsakova. 2011;2:105-109. (In Russ.).